Karyopharm Therapeutics Inc. — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 82/100
What the filing says
Karyopharm Therapeutics executed a Restructuring Support Agreement on November 2, 2026, with all major creditor classes and Ayrmid Ltd. The agreement contemplates a Chapter 11 filing in the Southern District of Texas with a DIP facility of $110M, a proposed merger with Ayrmid as stalking horse bidder, and a reorganization plan providing: Term Loan Lenders 36.1%-37.0% equity; 2028 Noteholders 6.4%-6.6% equity; 2029 Noteholders 33.3%-34.1% equity; Royalty Investors a 3% revenue royalty on selinexor over 5 years plus $18.75M liquidated damages; and Ayrmid 45% post-merger equity. All major debt holders ($128.98M term loans, $15.65M 2028 notes, $107.97M 2029 notes, $113.54M royalty claims) holding 100% are parties.
Why this rating
Company at $37M market cap faces bankruptcy with comprehensive debt restructuring. Material debt reduction via equity conversion, but company effectively acquired by Ayrmid at distressed valuation. Majority of enterprise value transferred to creditors; equity holders eliminated. Transformational event relative to company scale.
Price action (we called it negative)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.